Old Web
English
Sign In
Acemap
>
authorDetail
>
Holly Pavey
Holly Pavey
Cambridge University Hospitals NHS Foundation Trust
Medicine
Alirocumab
PCSK9
Internal medicine
Statin
4
Papers
8
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study.
2021
BMJ Open
Paul J. Cacciottolo
Michalis Kostapanos
Elena Hernan-Sancho
Holly Pavey
Fotini Kaloyirou
Evangelia Vamvaka
Joanna Helmy
Annette Hubsch
Carmel M. McEniery
Ian B. Wilkinson
Joseph Cheriyan
Show All
Source
Cite
Save
Citations (0)
132 Investigating the lowest threshold of vascular benefits from LDL lowering with a PCSK9 inhibitor in healthy volunteers – results from the intensity-low study
2020
Heart
Paul J. Cacciottolo
Michalis Kostapanos
Holly Pavey
Annette Hubsch
Ian B. Wilkinson
Joseph Cheriyan
Show All
Source
Cite
Save
Citations (0)
INvestigating the lowest Threshold of vascular bENefits from LDL cholesterol lowering with a PCSK9 mAb InhibiTor (alirocumab) in healthY volunteers – A mechanistic physiological study (INTENSITY-LOW): protocol and study rationale
2019
Journal of drug assessment
Michael S. Kostapanos
Paul J. Cacciottolo
Annette Hubsch
Holly Pavey
James Hurlock
Kaisa M. Mäki-Petäjä
Ian B. Wilkinson
Joseph Cheriyan
Show All
Source
Cite
Save
Citations (1)
High Water versus Ad libitum Water Intake for Autosomal Dominant Polycystic Kidney Disease: A Randomised Controlled Feasibility Trial
2019
QJM: An International Journal of Medicine
Ragada El-Damanawi
Michael C. Lee
Tess Harris
L B Cowley
Simon Bond
Holly Pavey
Richard N. Sandford
Ian B. Wilkinson
F.E. Karet Frankl
Thomas F. Hiemstra
Show All
Source
Cite
Save
Citations (7)
1